Kulvinder Kochar Kaur¹*, Gautam Allahbadia² and Mandeep Singh³

¹Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India
²Scientific Director, Rotunda-A Centre for Human Reproduction, Mumbai, India
³Consultant Neurologist, Swami Satyan and Hospital, Jalandhar, Punjab, India

*Corresponding Author: Kulvinder Kochar Kaur, Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India.

Received: September 15, 2021; Published: September 25, 2021

Abstract

With the greater advancements in field of cancer treatment, the survival rates have escalated remarkably, thus the need arising for the fertility preservation in the survivors with regards to oocyte/embryo/ovarian tissue cryopreservation has assumed great importance particularly for those receiving chemotherapy that too with alkylating agents. Furthermore, the need further is enhanced in younger adults along with adolescents diagnosed for cancer and need chemotherapy and are yet to attain puberty where it might not be feasible to do cryopreservation of oocytes. The aim of this short communication is to emphasize on the young cancer patients in whom a diagnosis of cancer is made and which patients stand a chance of generation of diminished ovarian reserve (DOR) who receive chemotherapy as well as the agents that justify evaluation of Antimullerian hormone (AMH) as well as other investigations required prior to initiation of chemotherapy.

Keywords: Cancer; Chemotherapy; Alkylating Agents; Fertility Preservation

References

1. Ethics Committee of the American Society of Reproductive Medicine. “Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion”. Fertility and Sterility 110 (2018): 380-386.
2. , et al. “Pre chemotherapy antimullerian hormone, age and body size predict timing of return of ovarian function in young breast patients”. Cancer 120 (2014): 3691-3698.
3. Woodruff TK., et al. “A view from the past into our collective future: the Oncofertility consortium vision statement”. Journal of Assisted Reproduction and Genetics 38 (2021): 3-15.
4. Anazodo A., et al. “How can we improve oncofertility care for patients? A systematic scoping review of current international practice and models of care”. Human Reproduction Update2 (2019): 159-179.
5. Smith BM., et al. “The National Physicians Cooperative transforming fertility management in the cancer setting and beyond”. Future Oncology 14 (2018): 3059-3072.
6. Vogt KS., et al. “Preserving Fertility in women with Cancer (PreFer) decision making and patientsreported outcomes in women offered egg and embryo banking prior to Cancer treatment”. Psychooncology 27 (2018): 2725-2732.
7. Kulvinder Kochar Kaur., et al. “An Update on Management of Oncofertility-Does the Use of Vsels Appear Practical in the Near Future in Human Malignancies Replacing Cortical Tissue/Testicular Tissue Transplantation”. International Journal of Stem Cells and Regenerative Medicine 1 (2019): 103.
8. Kulvinder Kochar Kaur., et al. “How Far Have We Reached with Regards to Our Endeavours in Testicular Tissue Transplantation Along with in Vitro Spermatogenesis After Success in Animals - A Systematic Review”. Archives of Urology12 (2020): 1-15.
9. Kulvinder Kochar Kaur., et al. “An update on fertility preservation in men undergoing cancer treatment, irrespective of age-A Comprehensive Review”.
10. Kulvinder Kochar Kaur., et al. “The mechanism by which chemotherapy with use of alkylating agents cause follicular activation: is there any further mode for the loss of the primordial follicles? A Short Communication”. Journal of Gynecology 3 (2021): 000222.
11. Hopeman MM., et al. “A predictive model for chemotherapy related diminished ovarian reserve in reproductive aged women”. Fertility and Sterility 115 (2021): 431-437.
12. Moore HC., et al. “Goserelin for ovarian protection during breast Cancer adjuvant cancer therapy”. The New England Journal of Medicine 372 (2015): 923-932.
13. Mehm AR., et al. “Fertility preservation in marrow failure syndrome prior to allogenic stem cells transplantation”. American Journal of Haematology 9372 (2018): E190-193.
14. Meirow D., et al. “Toxicity of chemotherapy and radiation on female reproduction”. Clinical Obstetrics and Gynecology 53 (2020): 727-739.
15. Brady PC and Forman EJ. “An Oncofertility prediction tool? Forecasting, fertility after Cancer”. Fertility and Sterility 115 (2021): 323-324.

Citation

Citation: Kulvinder Kochar Kaur., et al. “Significance of Fertility Preservation in Patients Undergoing Cancer Chemotherapy Specifically in Adolescents/Young Adults Requiring Alkylating Agent - A Short Communication”. Acta Scientific Cancer Biology 5.10 (2021): 22-25.

Copyright

Copyright: © 2021 Kulvinder Kochar Kaur., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.